Related references
Note: Only part of the references are listed.Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) plus capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).
Herbert Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program
Antoine Adenis et al.
BMC CANCER (2016)
Expressional STAT3/STAT5 Ratio is an Independent Prognostic Marker in Colon Carcinoma
Fee Klupp et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Novel immunotherapeutic activity of JAK and P13K delta inhibitors in a model of pancreatic cancer
Holly K. Koblish et al.
CANCER RESEARCH (2015)
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
Herbert I. Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
IL-22+CD4+ T Cells Promote Colorectal Cancer Stemness via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L
Ilona Kryczek et al.
IMMUNITY (2014)
INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells
H. J. An et al.
NEOPLASMA (2014)
Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer?
Graeme J. K. Guthrie et al.
CANCER TREATMENT REVIEWS (2013)
The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
Donald C. McMillan
CANCER TREATMENT REVIEWS (2013)
Impact of STAT3 Phosphorylation on the Clinical Effectiveness of Anti-EGFR Based Therapy in Patients With Metastatic Colorectal Cancer
Erion Dobi et al.
CLINICAL COLORECTAL CANCER (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Novel Role for STAT3 in Transcriptional Regulation of NK Immune Cell Targeting Receptor MICA on Cancer Cells
Romain Bedel et al.
CANCER RESEARCH (2011)
STAT3 Expression, Molecular Features, Inflammation Patterns, and Prognosis in a Database of 724 Colorectal Cancers
Teppei Morikawa et al.
CLINICAL CANCER RESEARCH (2011)
Immune microenvironments in solid tumors: new targets for therapy
Stephen L. Shiao et al.
GENES & DEVELOPMENT (2011)
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer
Michael S. Braun et al.
Therapeutic Advances in Medical Oncology (2010)
The Tumor Microenvironment in Colorectal Carcinogenesis
Vijay G. Peddareddigari et al.
CANCER MICROENVIRONMENT (2010)
Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells
Hua Xiong et al.
NEOPLASIA (2008)
Evolution of intratumoral genetic heterogeneity during colorectal cancer progression
L Losi et al.
CARCINOGENESIS (2005)
Share Paper
